Bio-Techne Announces Completion of Namocell Acquisition

JULY 05, 2022 MINNEAPOLIS, July 5, 2022 /PRNewswire/ — Bio-Techne Corporation (NASDAQ:TECH), today announced it has completed the acquisition of Namocell, Inc. The Namocell acquisition adds easy-to-use single cell sorting and dispensing platforms that are gentle to cells and preserve cell viability and integrity. Namocell’s instruments and consumables are critical technologies in various workflows in... Read more

Bio-Techne to acquire single-cell sorting platform provider Namocel

JUNE 22, 2022 MINNEAPOLIS and MOUNTAIN VIEW, Mo., June 22, 2022 /PRNewswire/ — Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced it has reached an agreement to acquire Namocell, Inc. Bio-Techne anticipates the acquisition to close in the first quarter of its... Read more

Bio-Techne and Carterra Initiate a Clinical Research Collaboration for COVID-19 Variant Analysis

SEPTEMBER 08, 2021 Companies bring together cutting-edge technologies and expertise to advance the world’s understanding of COVID-19 variants’ mechanism of action MINNEAPOLIS and SALT LAKE CITY, Sept. 8, 2021 /PRNewswire/ — Bio-Techne, a leading supplier of high-quality and innovative tools for life science research, therapeutic manufacturing and clinical diagnostics and Carterra Inc., the world leader in... Read more

Bio-Techne Joins Cell and Gene Therapy Catapult Process Analytical Technology Consortium

JUNE 08, 2021 MINNEAPOLIS, June 8, 2021 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced it is joining the Cell and Gene Therapy Catapult process analytical technology (PAT) consortium, which includes over 20 pharmaceutical companies, technology providers, therapy developers, and charities.  The consortium will assess the application and combination of multiple technologies for process analytics within... Read more

Bio-Techne and 908 Devices Announce Joint Collaboration

MAY 04, 2021 MINNEAPOLIS and BOSTON, May 4, 2021 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) and 908 Devices (NASDAQ: MASS) today announced a joint collaboration to develop an extended workflow solution for protein characterization. Bio-Techne, a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, and owner of the leading ProteinSimple... Read more

Bio-Techne Announces Commercial Release of Novel DNAscope In Situ Hybridization Assays for Chromogenic Detection of DNA Copy Number and Structural Variations

APRIL 27, 2021 Pushing the Spatial Genomics Frontier One Biomolecule at a Time from RNA to DNA MINNEAPOLIS, April 27, 2021 /PRNewswire/ — Bio-Techne Corporation (NASDAQ:TECH) today announced the expansion of the Advanced Cell Diagnostics (ACD), a Bio-Techne brand, RNAscope™ technology with release of new DNAscope Assays. The RNAscope technology is an advanced in situ hybridization (ISH)... Read more

Bio-Techne Announces Launch of Professional Assay Services – Dedicated Source for RNA In Situ Hybridization Assays in Spatial Gene Expression Analysis

APRIL 15, 2021 MINNEAPOLIS, April 15, 2021 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced that Advanced Cell Diagnostics (ACD), a Bio-Techne brand, completed an extensive rebranding effort in response to increased demand for its Assay Services offered at its Newark, CA laboratory. At the heart of this re-launch is a name change from Pharma... Read more

Bio-Techne Announces Licensing of Proprietary Antibody to Xencor for Therapeutic Development

MINNEAPOLIS, April 14, 2021 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced a license agreement for use of a proprietary Bio-Techne antibody by Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, for its therapeutic development pipeline. Bio-Techne is a global life sciences company providing... Read more

Bio-Techne Announces Commercial Release of Abby Automated Western System for Simple Western and Introduces Stellar Modules for Jess

Abby is the next generation chemiluminescence Western protein analyzer and Stellar modules set the standard for fluorescence sensitivity MINNEAPOLIS, April 8, 2021 /PRNewswire/ — Bio-Techne Corporation (NASDAQ:TECH) today announced that ProteinSimple, a Bio-Techne brand, released Abby, its next generation chemiluminescence system that automates traditional Western blotting.  This latest addition to the Simple Western product family offers... Read more

Bio-Techne Completes Acquisition of Asuragen, Inc.

MINNEAPOLIS, April 6, 2021 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed the acquisition of Asuragen, Inc.  The transaction included initial consideration of $215 million in cash plus contingent consideration of up to $105 million upon the achievement of certain future milestones.  The Asuragen acquisition adds a leading portfolio of best-in-class molecular... Read more